glycogen storage disease

(redirected from type IV)
Also found in: Thesaurus, Medical, Encyclopedia.
Related to type IV: Type IV collagen

glycogen storage disease

n.
Any of various genetic diseases caused by deficiency of one of the enzymes involved in breaking down or synthesizing glycogen, resulting in storage of abnormal amounts or types of glycogen and often affecting the liver, muscles, or both. Also called glycogenosis.
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.
Mentioned in ?
References in periodicals archive ?
Alport syndrome (AS) is a genetic disorder due to the inheritance of multiple defective genes which lead to production and deposition of abnormal type IV collagen [1].
A case of type IV renal tubular acidosis (RTA), a rare case of acute nephrotoxicity associated with CNI use, is detailed in this report.
Type IV: the existing technology is extremely difficult to develop, the general use of horizontal well volume modification and gas injection to add energy.
Upregulation of endothelin-1 (ET-1), vascular endothelial growth factor (VEGF), laminin (LN), and type IV collagen by LSECs during liver fibrosis has been reported [13-15].
25 June 2014 - Japanese pharmaceutical group Eisai Co Ltd (TYO:4523) and its diagnostics unit Eidia Co Ltd said Wednesday that Eidia would introduce in Japan the Panassay IV-C [Latex] measurement reagent kit assessing human type IV collagen in serum on July 2, 2014.
The study by researchers at Birkbeck, University of London and UCL revealed the mechanism of bacterial type IV secretion, which bacteria use to move substances across their cell wall.
Measurements of adhering cells showed that adhesion to bovine serum albumin-, type IV collagen- or laminin 1-coated plastic surfaces initially increased until donor age reached 30 y and then decreased.
The three recognized reactions to latex include nonallergic irritant contact dermatitis, type IV cell-mediated allergies and type I IgE-mediated allergies.
Type IV is looking for $1.5 million for start-up costs, and it hopes to treat 9 percent of the United States' wart patients within five years of receiving FDA approval.
It is safe for latex sensitive (Type I) and chemical sensitive (Type IV) healthcare professionals and patients.
Because infections caused by CA-MRSA isolated elsewhere are associated with the presence of the lukF gene encoding the Panton-Valentine leukocidin toxin and the staphylococcal chromosome cassette mec (SCCmec) type IV, the presence of both was evaluated by PCR, as described previously (9).